How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Phosphoinositide 3-Kinase Inhibitor Market
- By Drug Class: PI3K Alpha Inhibitors, PI3K Beta Inhibitors, PI3K Gamma Inhibitors, PI3K Delta Inhibitors, Pan-PI3K Inhibitors
- By Indication: Breast Cancer, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Non-Small Cell Lung Cancer, Other Solid Tumors
- By Route of Administration: Oral, Intravenous
- By Mechanism of Action: Selective PI3K Inhibition, Dual PI3K/mTOR Inhibition, Pan-PI3K Inhibition
- By End User: Hospitals, Specialty Clinics, Research Institutes
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - PI3K Alpha Inhibitors leads By Drug Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Phosphoinositide 3-Kinase Inhibitor Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
By Drug Class 5
By Indication 5
By Route of Administration 2
By Mechanism of Action 3
By End User 3
Companies profiled
Novartis AG
Gilead Sciences Inc.
Sanofi S.A.
Bristol-Myers Squibb Company
AstraZeneca plc
Pfizer Inc.
Merck & Co. Inc.
BeiGene Ltd.
TG Therapeutics Inc.
Infinity Pharmaceuticals Inc.
Calithera Biosciences Inc.
Verastem Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Gilead Sciences Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sanofi S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bristol-Myers Squibb Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →AstraZeneca plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Merck & Co. Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →BeiGene Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →TG Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Infinity Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Calithera Biosciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Verastem Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Zai Lab Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Kura Oncology Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Relay Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,752M by 2033 · 6.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- PI3K Alpha Inhibitors50.9
- PI3K Beta Inhibitors10.0
- PI3K Gamma Inhibitors15.6
- PI3K Delta Inhibitors15.0
- Pan-PI3K Inhibitors8.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,593M → $2,514M · 5.9%
Europe$1,110M → $1,725M · 5.7%
Asia Pacific$1,014M → $1,700M · 6.7%
Latin America$627.6M → $930.6M · 5.0%
Middle East and Africa$482.8M → $785.0M · 6.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.042026
6.062027
6.082028
6.092029
6.102030
6.122031
6.132032
6.132033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG15.8
- Gilead Sciences Inc.24.4
- Sanofi S.A.6.4
- Bristol-Myers Squibb Company12.0
- AstraZeneca plc5.8
- Pfizer Inc.7.7
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →By Drug Class18.4%
By Indication16.9%
By Route of Administration26.3%
By Mechanism of Action13.3%
By End User25.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.8
- Europe22.5
- Asia Pacific22.2
- Latin America12.2
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 75 | 76 | 91 | 90 | 93 | 96 | 87 |
| Gilead Sciences Inc. | 77 | 89 | 89 | 71 | 91 | 73 | 82 |
| Sanofi S.A. | 66 | 79 | 78 | 66 | 78 | 86 | 76 |
| Bristol-Myers Squibb Company | 76 | 60 | 59 | 72 | 70 | 78 | 69 |
| AstraZeneca plc | 54 | 54 | 62 | 67 | 52 | 57 | 58 |
| Pfizer Inc. | 71 | 70 | 47 | 52 | 69 | 68 | 63 |
| Merck & Co. Inc. | 64 | 47 | 42 | 53 | 43 | 50 | 50 |
| BeiGene Ltd. | 46 | 56 | 53 | 56 | 35 | 50 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Gilead Sciences Inc.
- Sanofi S.A.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ◐ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Gilead Sciences Inc. | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Sanofi S.A. | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Bristol-Myers Squibb Company | ◐ | ◐ | − | − | ◐ | ✓ |
| AstraZeneca plc | − | − | ◐ | ✓ | ◐ | ◐ |
| Pfizer Inc. | ◐ | ◐ | − | − | ◐ | ◐ |
| Merck & Co. Inc. | − | − | − | − | − | − |
| BeiGene Ltd. | ◐ | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG87
2Gilead Sciences Inc.82
3Sanofi S.A.76
4Bristol-Myers Squibb Company69
5Pfizer Inc.63
6AstraZeneca plc58
7Merck & Co. Inc.50
8BeiGene Ltd.49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Novartis AGGilead Sciences Inc.
Challenger2
Strong scale, closing on the leaders.
Sanofi S.A.Bristol-Myers Squibb Company
Contender2
Focused players with pockets of strength.
AstraZeneca plcPfizer Inc.
Niche2
Specialists in a single segment or region.
Merck & Co. Inc.BeiGene Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land By Drug Class in North America, then scale across Phosphoinositide 3-Kinase Inhibitor Market — a $238M beachhead inside a $4.02B market.
Beachhead (SOM)$238Mobtainable near-term
Serviceable (SAM)$1.40Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
PI3K Alpha Inhibitors
Best fit — highest urgency & budget in By Drug Class.
Economic buyer80 fit
PI3K Beta Inhibitors
Strong fit — clear ROI and a fast path to value.
End user69 fit
PI3K Gamma Inhibitors
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win By Drug Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add By Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + By Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel27%
Digital / self-serve23%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For By Drug Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Phosphoinositide 3-Kinase Inhibitor Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified23%
Evaluation12%
Closed-won6%
$20.2KCAC
$71KLTV
3.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Phosphoinositide 3-Kinase Inhibitor Market is a resilient opportunity — $6.00B by 2033, compounding at 4.4%.
TAM · 2025$4.26Btoday
TAM · 2033$6.00Bforecast
CAGR4.4%2027–2033
Cumulative$45.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.00BTotal addressable market
SAM$2.27BServiceable available market
SOM$493MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.4% CAGR
Demand compounds through 2033, outpacing GDP across By Drug Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in By Drug Class moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.00BLarge & growingTAM by 2033 at 4.4% CAGR
$2.27BServiceable nowreachable with today’s model
$493MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.68BBear2.8% CAGR
$6.00BBase4.4% CAGR
$7.68BBull5.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & By Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Phosphoinositide 3-Kinase Inhibitor Market — a $9.34B market by 2033. Plan: grow share from 8.4% to 14.8%.
Market size · 2033$9.34Btotal addressable
Market CAGR10.4%2027–2033
Target share14.8%from 8.4% today
Revenue ambition$1.38Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.4% | 14.8% | At risk |
| Revenue | $850M | $1.38B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 33.0% | 43.3% | At risk |
| Customer retention | 86.4% | 94.2% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in By Drug Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build By Indication capability
A defensible second engine — invest in By Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core By Drug Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch By Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $162M capacity & capability investment
- Greenlight bolt-on M&A in By Indication
- Authorise North America expansion plan
- Fund R&D program for By Drug Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Phosphoinositide 3-Kinase Inhibitor Market conversation — a $5.32B market you can size, segment and defend in minutes.
Market size · 2033$5.32Btotal opportunity
Growth10.6%CAGR to 2033
Addressable buyers1,574+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of By Drug Class
Goal Grow share in By Drug Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 4 mopayback period
$62K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Novartis AGGilead Sciences Inc.Sanofi S.A.Bristol-Myers Squibb CompanyAstraZeneca plcPfizer Inc.Merck & Co. Inc.BeiGene Ltd.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Phosphoinositide 3-Kinase Inhibitor Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Phosphoinositide 3-Kinase Inhibitor Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Phosphodiesterase Inhibitor Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportPhosphodiesterase-5 Inhibitor Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportPhosphodiesterase-4 Inhibitor Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportPhospho AKT Antibody Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportPhosphatidylserine Supplement Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportPhosphate Buffered Saline (PBS) Tablet Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportPhosphate-Buffered Saline (PBS) Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportPhosphate Buffered Saline Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportPhosphatase Assay Service Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportPhoropters and Autorefractors Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportPhonocardiography Instrument Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportPholcodine API Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.